Safety and Early Efficacy of iPSC-Derived Motor Neuron Cells (XS228) in Subacute Spinal Cord Injury: A Phase I Trial

Launched by THIRD AFFILIATED HOSPITAL, SUN YAT-SEN UNIVERSITY · May 8, 2025

Keywords

ClinConnect Summary

This clinical trial, called the Phase I Trial of iPSC-Derived Motor Neuron Cells (XS228), is designed to explore the safety and initial effectiveness of a new treatment for people with spinal cord injuries (SCI). Specifically, the study will look at how well a type of cell, derived from stem cells, can be safely transplanted into the spinal cord of adults who have suffered from SCI between 14 to 60 days prior. The main goal is to determine the highest dose of these cells that can be given without causing harmful effects.

To participate, individuals must be between 18 and 65 years old and have a specific type of spinal cord injury confirmed by MRI. Participants will undergo various tests to ensure they qualify and will then receive the cell transplant, followed by monitoring for up to one year to check their recovery and any side effects. It’s important to note that certain health conditions, such as severe infections or significant heart problems, may exclude someone from participating. Overall, this trial aims to provide valuable insights into a promising new treatment for spinal cord injuries.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age: 18 to 65 years (inclusive), regardless of gender.
• • Etiology: Cervical (C4) to lumbar (L2) spinal cord injury (SCI) caused by traumatic injury or surgery-related factors.
• Severity:
• • Classified as ASIA Impairment Scale (AIS) Grades A, B, or C. MRI-confirmed evidence of spinal cord injury.
• Disease Stage:
• • Primary SCI occurring 14 to 60 days prior to screening (subacute phase).
• Contraception:
• • Participants of childbearing potential (male and female) must agree to use effective non-hormonal contraceptive methods during the trial and for 6 months after trial completion.
• Compliance:
• • Voluntarily participate in the clinical study. Ability to understand and comply with study procedures. Participant or legal guardian can provide written informed consent.
• Exclusion Criteria:
• • Neurological Inability
• • Primary spinal cord injury (SCI) during screening with concomitant severe traumatic brain injury precluding neurological function assessment.
• • Respiratory/Circulatory Instability
• • High cervical SCI (C1-C3) causing respiratory/circulatory compromise requiring endotracheal intubation or tracheostomy.
• • Life-Threatening Multiorgan Dysfunction
• • Concurrent severe injuries to other organ systems with life-threatening dysfunction.
• • Unstable Thoracoabdominal Injuries
• • Injuries to lungs, liver, kidneys, spleen, etc., deemed unstable by the investigator.
• • Prior Spinal Pathology
• • History of SCI or coexisting spinal disorders (e.g., ankylosing spondylitis, spinal deformities, primary/metastatic spinal tumors, spinal vascular malformations, syringomyelia).
• • Local Infection/Increased ICP
• • Active infection at the lumbar puncture site or intracranial hypertension during screening.
• • Severe Infections
• • Sepsis, septic shock, or severe pneumonia (per IDSA/ATS 2007 diagnostic criteria).
• • Confounding Neurological/Psychiatric Conditions
• • Parkinson's disease, severe dementia, myasthenia gravis, stroke, Guillain-Barré syndrome, diabetic neuropathy, or other conditions interfering with study assessments.
• Cardiac Abnormalities (any of the following):
• • Congestive heart failure (NYHA Class III/IV). Severe uncontrolled arrhythmias (e.g., sick sinus syndrome, third-degree AV block).
• • Unstable angina or acute myocardial infarction within 3 months prior. Pulmonary Complications
• • Pulmonary hypertension, pulmonary embolism, or suspected embolism during screening.
• • Uncontrolled Hypertension/Hypotension
• • Systolic BP \>160 mmHg or diastolic BP \>100 mmHg; or systolic BP \<90 mmHg or diastolic BP \<60 mmHg.
• • Active Autoimmune Diseases
• • Requiring immunosuppressants (e.g., uncontrolled hyperthyroidism, systemic lupus erythematosus).
• • Immunosuppressant Non-Compliance
• • Unwillingness or inability to use immunosuppressants per protocol.
• Laboratory Abnormalities (any of the following):
• • ALT/AST \>2×ULN or total bilirubin \>2×ULN. eGFR \<60 mL/min/1.73m² (CKD-EPI 2021 formula). APTT/PT \>2.5×ULN (without anticoagulants). Platelets \<100×10⁹/L or hemoglobin \<90 g/L. Allergy
• • History of severe allergies or hypersensitivity to trial drug/excipients (human albumin, lactated Ringer's solution).
• • Infectious Diseases
• • HBsAg+ with HBV DNA \>1000 IU/mL; HCV-Ab+; HIV-Ab+; or TP-Ab+. Lumbar Puncture Refusal
• • Unwillingness to undergo intrathecal administration procedures. Pregnancy/Lactation
• • Females who are pregnant or breastfeeding. Malignancy
• • Active malignancy or anticancer therapy within 5 years prior. Recent Clinical Trial Participation
• • Enrollment in another drug trial within 3 months prior. Investigator Discretion
• • Any condition deemed unsuitable for participation by the investigator.